~ Innocan Pharma Corporation, a leading pioneer in the pharmaceutical and biotechnology industries, has recently made a significant impact at the PAINWeek conference in Las Vegas. The company's LPT-CBD poster presentation, delivered by Dr. Joseph V. Pergolizzi Jr., MD, MBA, sparked genuine enthusiasm among conference participants.

The presentation caught the attention of Pain Medicine News, a prominent pain publication in the United States. The publication has selected the poster for a dedicated video interview that is expected to be featured on its website within the next two weeks. This recognition from Pain Medicine News is a testament to the potential of Innocan's LPT-CBD treatment for pain relief.

The PAINWeek conference is a highly esteemed event that brings together thousands of leading clinicians, researchers, educators, and potential pharmaceutical partners in the field of pain medicine. It provides a unique opportunity for professionals to connect, share ideas, and highlight new approaches in pain management.

During the conference, Dr. Pergolizzi presented data from a narrative review that highlighted the limitations of plant-derived CBD oils in treating chronic pain and emphasized the urgent need for regulated, long-acting synthetic CBD therapies. Additionally, preclinical data was presented that demonstrated the prolonged pharmacokinetics and extended pain relief of LPT-CBD after a single administration to dogs and minipigs.

The poster presentation received strong interest at the conference as it showcased the potential of LPT-CBD as an innovative solution for chronic pain management through a single injection. Top key opinion leaders and subject matter experts in the pain field were also interviewed by Pain Medicine News expressing positive views on LPT-CBD's potential to advance pain management.

More on nvtip.com

• DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
• CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
• Phinge Explains The Core Safety Principals Of Netverse, Its Patented App-less Platform & Technology Accessed Only Though Its Patented Phones & Devices
• Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
• 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus

Dr. Joseph V. Pergolizzi Jr., MD, MBA, who serves as both Poster Presenter and Member of Innocan's Advisory Board stated: "What makes this asset so unique is not just its novel approach to pain relief, but the way it was received by colleagues at PAINWeek. The enthusiasm in the room was palpable because this technology represents a true breakthrough opportunity to address longstanding unmet needs in pain management. For patients, that means the potential for meaningful improvements in their daily lives and relief from complaints that have gone unanswered for far too long."

Iris Bincovich, Chief Executive Officer of Innocan, also expressed excitement about the positive response and recognition received at PAINWeek. She stated: "We are very excited to expose our unique technology among thousands of leading clinicians and potential pharmaceutical partners. The favoring response and recognition received during PAINWeek shows our dedication to advancing evidence-based care and bringing real solutions that matter to patients and providers."

Innocan is an innovator in both the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the company has developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan focuses on developing and marketing a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle.

More on nvtip.com

• BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
• NJTRX Positions for Next-Generation Asset Trading with U.S. Regulatory Framework
• EliTe Solar Unveils Refreshed Corporate Identity to Mark 20th Anniversary
• BCI Shines at the RE+2025 Energy Expo in Las Vegas
• Poncho Tha Popstar: The West's Next King

For further information about Innocan Pharma Corporation, please contact CEO Iris Bincovich at +1 5162104025 or +972-54-3012842 or +442037699377.

Please note that neither the Canadian Securities Exchange nor its regulation services provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information:

This news release contains forward-looking information within the meaning of applicable securities laws. This includes statements regarding Innocan's use of LPT-CBD as a treatment for pain relief and its potential to advance pain management. Such forward-looking information is based on current expectations, estimates, projections, and assumptions made by Innocan's management in light of its experience and perception of historical trends, current conditions, and expected future developments, as well as other factors that it believes are appropriate and reasonable in the circumstances. However, there can be no assurance that such expectations will prove to be correct. Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information. These factors include but are not limited to: risks associated with the pharmaceutical industry in general; the success of Innocan's LPT-CBD treatment; and the potential for regulatory approval of LPT-CBD. Innocan cautions readers not to place undue reliance on any forward-looking statements made by Innocan. The company does not undertake any obligation to update or revise any forward-looking statements except as required by applicable securities laws.

---

Show All News | Report Violation